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Pilot Study of Twice-weekly Therapy for Pulmonary
Tuberculosis in Taiwan
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Background/Purpose: Taiwan has never implemented supervised intermittent chemotherapy for pul-
monary tuberculosis, and its application and results are unknown. The purpose of this study was to evalu-
ate the efficacy and feasibility of a 62-dose, four-drug, 6-month, twice-weekly regimen administered by
directly observed therapy for the treatment of pulmonary tuberculosis.
Methods: From January 2004 through December 2006, a total of 116 patients with suspected or con-
firmed pulmonary tuberculosis were enrolled. Thirty-two of these patients were excluded from the analy-
sis because of drug resistance, negative culture, self withdrawal and drug reactions. Isoniazid, rifampin,
pyrazinamide, and ethambutol were administered daily for 2 weeks, followed by twice weekly at a higher
dose for 6 weeks. Thereafter, isoniazid, ethambutol and rifampin were administered twice weekly for 18
weeks. Treatment was directly observed by nurses or outreach workers.
Results: Of the 84 evaluable patients, 75 [89.3%, 95% confidence interval (CI): 80.6–95.0%] patients
were considered as successfully treated, three (3.6%, 95% CI: 0.7–10.1%) transferred out, five (6.0%, 95%
CI: 2.0–13.3%) were unsuccessful and one (1.2%, 95% CI: 0.03–6.5%) died. Five patients were treatment
failure (6.0%, 95% CI: 2.0–13.3%). Three patients had recurrences of pulmonary tuberculosis, and the 
recurrences were 4, 6 and 15 months after the completion of therapy. Six patients (5.2%) had severe adverse
drug reactions and had their regimen modified.
Conclusion: Prior to this study, intermittent therapy has not been attempted in Taiwan. This four-drug,
mostly twice-weekly pulmonary tuberculosis treatment regimen is efficacious and relatively nontoxic, with
a higher treatment success rate and a lower death rate. It considerably simplifies treatment and facilitates the
execution of directly observed therapy. The reasons for the relatively high failure rate require further studies.
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Tuberculosis (TB) continues to be a serious public
health threat in Taiwan. In 2008, the notification
rate of TB was 62.0 per 100,000 people.1 Because of
the low self-administered treatment success rates
(under 80%) and emergence of multidrug resis-
tant strains, directly observed therapy (DOT) has
been highly recommended by the World Health
Organization (WHO) and the International Union
DOT for TB in Taiwan
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Against Tuberculosis and Lung Disease as the stan-
dard of care for treatment of pulmonary TB.2,3
The World Bank considers TB control as one of
the most cost-effective of available health inter-
ventions.4 The goals of DOT are to ensure timely
and complete compliance of patients and to pre-
vent the development of multidrug resistance.
To better control the spread of TB, the World
Health Assembly (WHA) established two goals
in 1991: (1) to detect at least 70% of new smear-
positive cases; and (2) to successfully treat at least
85% of these cases.5 In 2007, 5.5 million TB cases
were notified by directly observed therapy short-
course (DOTS) programs (99% of total case 
notifications). This included 2.6 million smear-
positive cases. Globally, the rate of treatment suc-
cess for new smear-positive cases treated in DOTS
programs in 2006 reached the target of 85%.6
In Taiwan, from 2001 to 2003 treatment success
rates ranged from 73.8% to 79%. Death rates
ranged from 17.8% to 20.1%, default rates ranged
from 1.7% to 5.2%, and the treatment failure rate
was 0.4%.7 While the low success rates were due
to the high death rates, the final results still failed
to meet the standards set out by the WHA.
Taiwan has never implemented DOT and its
application and results are unknown. Therefore,
the purpose of our study was to evaluate the effi-
cacy and toxicity of a four-drug, 6-month, mostly
twice-weekly, and directly observed regimen for
treatment of pulmonary TB with a minimal num-
ber of doses (62 doses).
Materials and Methods
Patient population
From January 2004 through December 2006, we
enrolled smear positive patients with no known
history of TB from the Buddhist Tzu Chi Medical
Center and Mennonite Hospital. All patients were
residents of Hualien County, Taiwan.
Inclusion and exclusion criteria
Study participants had to be at least 18-years-old
with no previous history of TB. Participants had
to have at least one sputum specimen smear pos-
itive for acid-fast bacilli and at least one pre-
treatment sputum specimen culture positive for
Mycobacterium tuberculosis. The organism has to be
sensitive to isoniazid, rifampin, and ethambutol.
Patients with an unconfirmed diagnosis of TB were
conditionally enrolled and subsequently with-
drawn if a pre-treatment sputum culture did not
yield M. tuberculosis that was fully susceptible to
isoniazid, rifampin, and ethambutol. A posterior-
anterior chest roentgenogram had to be consistent
with active pulmonary tuberculosis.
Exclusion criteria included extrapulmonary TB,
contraindications to the medications (isoniazid,
rifampin, pyrazinamide or ethambutol), preg-
nancy, previous treatment of 14 days or more of
anti-TB treatment prior to enrollment to this study,
or presence of immunosuppressive disorders such
as lymphoma or human immunodeficiency virus.
Additional exclusion criteria included patients
with liver cirrhosis, uremia, under immunosup-
pressive therapy, or in a critical condition. We also
excluded participants from whom informed con-
sent could not be obtained.
Treatment regimen, modifications, and
administration of drugs
Table 1 provides details of the treatment regimen.
All patients were hospitalized for the first 2 weeks
(where isoniazid, rifampin, pyrazinamide, and
ethambutol were given daily) and subsequently
treated in a non-medical setting where patients
received the medications twice weekly in higher
dosages (except for rifampin) for 6 weeks. After-
wards, isoniazid, ethambutol and rifampin were
given twice weekly for 18 weeks, thereby complet-
ing 26 weeks of therapy with a total of 62 doses.
The treatment duration could be lengthened to 
9 months if cavitations were present on the initial
chest radiograph or the culture at the time of
completion of 8 weeks of therapy remained pos-
itive or patients had diabetes mellitus.8–10
Twice-weekly doses were administered at the
patient’s residence or workplace under the direct su-
pervision of nurses or outreach workers on a mon-
day and Thursday or Tuesday and Friday schedule.
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Clinical and laboratory monitoring
Before initiation of treatment, all patients under-
went a complete history and physical examination,
with specific evaluation for previous antitubercu-
lous treatment, family history of tuberculosis, other
medical illnesses and medications, history of alco-
hol use, job history, race, sex, and age. All patients
had at least three pre-treatment sputum examina-
tions for smears and cultures. Indirect susceptibility
testing was performed on at least one pre-treatment
isolate after subculture, using standard agar pro-
portion methods. All patients had posterior-
anterior and lateral chest roentgenograms.
Other pre-treatment tests included biochemi-
cal studies such as chemistry panels and complete
blood counts, human immunodeficiency virus
antibody testing (after providing written permis-
sion), and visual testing (for monitoring side 
effects of ethambutol).
During the course of therapy, patients were
clinically monitored for nausea, anorexia, pete-
chiae, skin rashes, visual disturbances, or any other
symptoms. Suspicious drug adverse effects were
worked up accordingly. One sputum specimen for
an acid-fast bacilli smear and culture was obtained
after 4, 8, 12, 16, 20, and 24 weeks of therapy. 
A posterior-anterior chest roentgenogram was ob-
tained after 8 and 26 weeks and at the discretion
of the attending physician.
After completion of therapy, patients were fol-
lowed up for 2 years. Chest roentgenograms were
performed annually during this time frame. If any
abnormalities were noted or if attending physi-
cians had any clinical suspicions, sputum was
collected and sent for acid-fast bacilli smear and
culture. Patients were directed to report back to
the hospital if they developed any symptoms
consistent with recurrent tuberculosis, such as
chronic cough, fever, or weight loss.
Definition of treatment outcomes and
recurrence
Six standard and mutually exclusive categories were
used to define treatment outcomes as set forth by
WHO: cured, treatment completed, death, default,
failure, and transferring out of the program.11,12
Cured was defined as a patient who completed
treatment and was sputum culture negative in the
last 2 months of treatment and on at least one
previous occasion. Treatment completed was de-
fined as a patient who had completed treatment
but who did not meet the criteria to be classified
as cured or failed. Failure was defined as a patient
who remained or reverted back to sputum culture
positive during the last 2 months of treatment.
Death was defined as a patient who died for any
reason during the course of treatment. Default
was defined as a patient whose treatment was 
interrupted for 2 consecutive months or more.
Transferred out was defined as a patient who had
been transferred to another recording/reporting
unit. Successfully treated was defined as a patient
who was cured or had completed treatment.
A sputum conversion was defined as: 1) the
earliest time in which sputum culture is negative
for M. tuberculosis, and 2) it remains negative
thereafter.
A recurrence was defined by at least one posi-
tive culture for M. tuberculosis at any time up to
24 months after completion of the regimen.
Table 1. A 62-dose, 4-drug, 6-month therapy for
pulmonary tuberculosis, the Hualien regimen
Daily dosage for the first 2 weeks
Isoniazid 300 mg
Rifampin 600 mg
Pyrazinamide 1500 mg Body weight ≤ 50 kg
2000 mg Body weight > 50 kg
Ethambutol 800 mg Body weight ≤ 50 kg
1200 mg Body weight > 50 kg
Weeks 3–8 (Twice weekly dosage)
Isoniazid 15 mg/kg body weight (max 900 mg)
Rifampin 600 mg
Pyrazinamide 3000 mg body weight ≤ 50kg
3500 mg body weight > 50kg
Ethambutol 50 mg/kg body weight
Weeks 9–26 (Twice weekly dosage)
Isoniazid 15 mg/kg body weight (max 900 mg)
Rifampin 600 mg
Ethambutol 50 mg/kg body weight
DOT for TB in Taiwan
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Statistical analysis
Statistical analysis was performed using STATA
version 8.0 (STATA Corp., Houston, TX, USA).
The exact (Clopper-Pearson) 95% confidence in-
terval was calculated for a single proportion.
Fisher’s exact test was used to determine the asso-
ciation of categorical variables. A p value < 0.05
was considered to be statistically significant and
all tests were two-sided.
Results
From January 2004 through December 2006, 116
patients with known or suspected pulmonary tu-
berculosis were enrolled in this study. Thirty-two
patients were excluded from analysis. Four pa-
tients voluntarily withdrew from the study because
of personal reasons, 15 had resistant strains (7 had
strains resistant to isoniazid only, 1 had a strain
resistant to rifampin only, and 7 had strains re-
sistant to isoniazid and rifampin), six had smear-
positive but culture-negative non-TB pulmonary
disease, one had extra-pulmonary involvement
(middle ear), and six had their treatment modified
because of a severe adverse drug reaction (4 pa-
tients had severe hepatic dysfunction, 1 had severe
vomiting, and 1 had severe skin rash).
Table 2 shows the demographics and clinical
characteristics of the remaining 84 evaluable 
patients. Table 3 shows the treatment outcomes
of the 84 patients. Seventy-five [89.3%, 95% con-
fidence interval (CI): 80.6–95.0%] patients were
considered a treatment success, three (3.6%,
95% CI: 0.7–10.1%) transferred out, five (6.0%,
95% CI: 2.0–13.3%) failed, and one (1.2%, 95%
CI: 0.03–6.5%) died. Three patients were trans-
ferred to another county. They received self-
administered treatments and responded favorably.
Of the five patients who failed, three were cured
after re-treatment with the same regimen, two
developed resistance to isoniazid and rifampin
and were cured after 2 years of treatment using
second line medications. One patient died of un-
known causes after 5 months of treatment. No
patients defaulted. Of the 75 successfully treated
patients, most patients received 6 months of treat-
ment, but 24 (32%) patients received 9 months
of treatment.
Table 3 shows the factors associated with treat-
ment outcomes. Males and aboriginal Taiwanese
patients were more likely to fail. Alcohol users
were more likely to fail or transfer out. However,
these associations were not statistically significant.
Other than the six patients (5.2%) who had
severe adverse drug reactions and had their regi-
men modified, common minor side effects were
encountered in 44 patients: there was gastroin-
testinal intolerance in 12, cutaneous abnormali-
ties of rash or pruritus in 27, arthralgia in 19, and
blurred vision in nine patients.
The regimen succeeded in achieving lasting
bacteriologic conversion in 76 (93.8%) of the 81
patients who completed therapy, including the
five with bacteriologic failure.
Table 4 shows the time for conversion to neg-
ative sputum cultures. Of 81 patients, the culture
results converted to negative in 18 (22.2%) patients
Table 2. Demographics and clinical characteristics
of the 84 evaluable patients
Characteristics n %
Sex
Female 30 35.7
Male 54 64.3
Age (yr)
18–24 6 7.1
25–44 33 39.3
45–64 31 36.9
≥ 65 14 16.7
Diabetes mellitus
Yes 22 26.2
No 62 73.8
Indigenous Taiwanese
Yes 56 66.7
No 28 33.3
Alcohol user
Yes 55 65.5
No 29 34.5
Cavitation on CXR
Yes 44 52.4
No 40 47.6
CXR = chest x-ray.
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within 4 weeks, in 43 (53.1%) patients within 
8 weeks, in 64 (79.0%) patients within 12 weeks,
in 73 (90.1%) patients within 16 weeks and in
76 (93.8%) patients within 20 weeks.
Of the 75 successfully treated patients, 62
(82.7%) were followed-up for 24 months. Thirteen
patients were not assessed in 2 years time, six died
of causes unrelated to TB, two were lost to follow-
up, and five were non-compliant to follow-up but
were known to be doing well at the 2-year mark.
Three patients (4.8%) had recurrences of pul-
monary tuberculosis. These occurred 4, 6 and 
15 months after the completion of therapy. All pa-
tients had positive sputum culture for M. tubercu-
losis, and their clinical features and radiographic
findings were supportive of recurrent tubercu-
losis. The recurrent strains were fully drug sus-
ceptible, and they all received another 1 year of
treatment that resulted in curative outcomes.
Discussion
In this pilot study of four-drug, twice weekly, di-
rectly observed therapy in eastern Taiwan, we ob-
served an excellent treatment success rate of almost
Table 3. Treatment outcomes by sex, age group, indigenous Taiwanese race, diabetes mellitus, drinking
habit and the presence of cavitations on chest radiography
n Treatment success Died Failed Transfer p
Sex 0.483
Male 54 46 (85.2) 1 (1.9) 4 (7.4) 3 (5.6)
Female 30 29 (96.7) 0 (0.0) 1 (3.3) 0 (0.0)
Age (yr) 0.853
< 24 6 6 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
25–44 33 29 (87.9) 0 (0.0) 2 (6.1) 2 (6.1)
45–64 31 28 (90.3) 1 (3.2) 1 (3.2) 1 (3.2)
≥ 65 14 12 (85.7) 0 (0.0) 2 (14.3) 0 (0.0)
Diabetes mellitus 0.367
Yes 22 20 (90.9) 1 (4.6) 1 (4.6) 0 (0.0)
No 62 55 (88.7) 0 (0.0) 4 (6.5) 3 (4.8)
Aboriginal Taiwanese 0.312
Yes 56 49 (87.5) 0 (0.0) 4 (7.1) 3 (5.4)
No 28 26 (92.9) 1 (3.6) 1 (3.6) 0 (0.0)
Alcohol user 0.091
Yes 55 47 (85.5) 0 (0.0) 5 (9.1) 3 (5.5)
No 29 28 (96.6) 1 (3.5) 0 (0.0) 0 (0.0)
Cavitations on CXR 0.740
Yes 44 40 (90.9) 0 (0.0) 3 (6.8) 1 (2.3)
No 40 35 (87.5) 1 (2.5) 2 (5.0) 2 (5.0)
Total 84 75 (89.3) 1 (1.2) 5 (6.0) 3 (3.6)
Data are presented as n or n (%). CXR = chest x-ray.
Table 4. Time for conversion to negative sputum
cultures (n = 81)*
Week of Cumulative percentage of 
therapy patients who were culture negative
4 22.2
8 53.1
12 79.0
16 90.1
20 93.8
24 93.8
*Excludes three patients who transferred out.
DOT for TB in Taiwan
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90%. The regimen and dosing method were well
tolerated by our study participants. The relapse
rate was within the 5% goal in the guidelines 
of the American Thoracic Society.13 To our knowl-
edge, this is the first intermittent dosing study and
the first DOT in Taiwan. The results of our study
support the DOTS strategy that has been fully im-
plemented in Taiwan since 2006, and suggest that
the convenient twice weekly regimen could be 
a feasible alternative to the currently used daily
regimen in a field setting similar to this study.
According to the USA’s Centers for Disease
Control’s 1986 research on TB treatment, they rec-
ommended 2 months of isoniazid, rifampin and
pyrazinamide, followed by 4 months of isoniazid
and rifampin.14 Using this regimen can achieve
excellent results of over 95% cure rates. In certain
areas where drug resistance is an issue, ethambutol
can be added to the regimen. At the time our study
was planned, the standard anti-TB chemotherapy
regimen in Taiwan was a 6-month four-drug reg-
imen given daily via a self-administered method.
In 1993, WHO began recommending DOTS,
where patients take drugs under the direct obser-
vation of health care workers. This has been shown
to be effective in achieving a high successful treat-
ment rate, from 86% to 96.5%.15 According to
Jasmer et al, DOT was significantly associated with
a higher treatment success rate compared with self-
administered therapy (97.8% vs. 88.6%, p<0.002)
and a lower tuberculosis-related mortality rate
(0% vs. 5.5%, p = 0.002).16 DOT also leads to 
significant reductions in the frequency of pri-
mary drug resistance, acquired drug resistance
and relapse.17
The DOTS strategy for TB control was launched
by WHO in 1995.18 Taiwan Centers for Disease
Control was initially reluctant to follow the WHO
guidelines and unsatisfactory treatment outcomes
were subsequently noted. This pilot study of DOT
aimed to prove the efficacy and safety of DOT in
Taiwan.
Table 5 compares the treatment outcomes of
new smear-positive tuberculosis in 2004–2006 in
Taiwan with those of cases included in this study
and with those of the WHO report in 2009 on
global TB control. The treatment success rate of
89.3% in this study is higher than the target of
85% first set by the WHA in 1991, and is much
higher than the treatment success rate in Taiwan.
The major difference in our study is the death rate.
The Hualien regimen can maintain the death rate
below 2% compared with the 20% death rate in
Taiwan. There are three possible reasons for such
significant differences in mortality rates. First, 
we excluded patients who had a critical condi-
tion. Second, our patient base mostly comprised
younger age groups (Table 2). Finally, and most
importantly, previous Taiwan TB studies did not
use DOT in their treatment strategy.
The only weak point in the Hualien-regimen
outcome is that our failure rate (6.0%) appears
to be higher compared with the global average
(1.6%). This issue requires further study. Of the
five patients who had failed treatment, two (40%)
developed multidrug resistant-TB. However, a re-
view of literature showed that other studies have
comparable, if not higher, rates in development
of multidrug resistant-TB. In previous Taiwanese
and Peruvian studies, the multidrug resistant-TB
Table 5. Comparison of treatment outcomes for new smear-positive tuberculosis cases in 2004–2006 in
Taiwan, in Hualien and the results of the WHO report on global tuberculosis control
Cured
Completed 
Died Failed Defaulted Transferred
Not Treatment 
treatment Evaluated success (%)
Taiwan 2004 15.7 45.3 23.4 0.6 1.2 0.2 13.6 61.0
Taiwan 2005 40.6 23.4 24.0 1.7 2.3 0.1 7.8 64.1
Taiwan 2006 31.6 35.4 22.3 3.3 2.5 0.0 4.8 67.0
Hualien study 2004–2006 82.1 7.1 1.2 6.0 0.0 3.6 0.0 89.3
Global 2006, DOTS 78.0 6.3 4.2 1.6 5.0 2.5 2.2 85.0
WHO = World Health Organization; DOTS = directly observed therapy short-course.
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development rate was 67% and 94%, respectively,
among patients who received re-treatment after
failure.19 Fortunately, all of our five patients had
favorable outcomes after re-treatment.
Levels of disease recurrence after successful
treatment range from 0% to 14%.20–26 Patients
cured with this regimen have a lower relapse rate
2 years after treatment completion. The 2-year 
relapse rate of 4.8% for new smear-positive cases
in our study performed under actual field condi-
tions is comparable to the relapse rates of other
DOTS clinical trials.20–26
A recent large case-control study from Hong
Kong found that relapse was significantly asso-
ciated with cavitation on initial chest radiogra-
phy, positive culture after completing 2 months
of therapy, and diabetes mellitus. DOT signi-
ficantly reduces the risk of relapse, and the risk
might be further reduced by prolonging treat-
ment.10 The Hualien regimen is similar to a pre-
vious trial in Denver.27 This study differs from the
Denver regimen in two ways. Our regimen used
ethambutol instead of streptomycin, thus avoid-
ing injections (which is more convenient and
helps to avoid transmission of human immun-
odeficiency virus).28 The second difference is that
we prolonged treatment to 9 months for those
patients with high risk factors, such as cavitations
on chest radiographs, positive sputum culture at
2 months, and diabetes mellitus. The results of
the Hualien regimen are comparable with the
Denver regimen.
The most important limitation of this study is
that there was no comparative control group.
Therefore, we were not able to infer directly if
our regimen was better than self-administration
or daily dosing in our setting. Another limitation
is that there was primary drug resistance in a sub-
stantial percentage of patients. By excluding
these patients from our study, this negatively af-
fected our sample size.
Since April 2006, Taiwan has implemented
DOTS on a full scale. Our findings suggest that a
four-drug, intermittent (twice weekly) tuber-
culosis treatment regimen may achieve great suc-
cess in reaching higher treatment success rates,
lowering TB-related death rates, and saving costs
via minimizing the number of encounters of DOT
in Taiwan. Although the relatively higher failure
rate is a major concern, we are currently under-
taking further studies to clarify this difference.
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